Key result
Minimally invasive mitral repair for Barlow disease yields zero mortality and ~12% moderate MR at mid-term.
Why the study?
Surgical repair of Barlow's disease is technically complex because lesions involve multiple mitral leaflet scallops. Data on the mid-term outcomes of minimally invasive mitral valve repair using valve-preserving techniques in Barlow's disease were limited.
Does minimally invasive mitral valve repair using valve-preserving techniques provide favorable mid-term clinical and echocardiographic outcomes in patients with severe mitral regurgitation due to Barlow’s disease?
Cohort (n=26)
No
Does minimally invasive mitral valve repair using valve-preserving techniques provide favorable mid-term clinical and echocardiographic outcomes in patients with severe mitral regurgitation due to Barlow’s disease?
Minimally invasive mitral valve repair using leaflet-preserving techniques in Barlow's disease is safe and durable at mid-term follow-up, achieving a 100% freedom from reoperation and mortality with an 88.5% rate of none-to-mild residual regurgitation.
Supports mid-term safety of minimally invasive repair in Barlow's disease; leaves open need for randomized trials to confirm durability.
Introduction: Barlow’s disease is a form of degenerative mitral valve disease characterized by lesions involving multiple scallops of the mitral leaflets, making surgical repair technically complex and challenging. In such cases, mitral valve repair using valve-preserving techniques through a minimally invasive approach offers several advantages for patients. However, data regarding the mid-term outcomes of minimally invasive mitral valve repair using valve-preserving techniques in Barlow’s disease remain limited. Therefore, this study was conducted to evaluate these outcomes. Methods: This retrospective cohort study included all patients with severe mitral regurgitation due to Barlow’s disease who underwent minimally invasive mitral valve repair using valve-preserving techniques at the University Medical Center Ho Chi Minh City from 2020 to 2024. Patients were followed up continuously for a period ranging from 6 months to 5 years. Results: A total of 26 patients with severe mitral regurgitation due to Barlow’s disease underwent minimally invasive mitral valve repair using valve-preserving techniques. The mean follow-up duration was 29.9 ± 19.8 months. During follow-up, no mortality or reoperation was observed. Three patients (11.5%) developed moderate mitral regurgitation, while the remaining patients had either no regurgitation or only mild mitral regurgitation. Conclusion: Minimally invasive mitral valve repair for Barlow’s disease using valve-preserving techniques demonstrated favorable mid-term outcomes, with a low rate of recurrent moderate or greater mitral regurgitation and no cases requiring reoperation.
No takes yet. Share an insight, caveat, or question.
Lương et al. (2026) conducted a cohort in Severe mitral regurgitation due to Barlow's disease (n=26). Minimally invasive mitral valve repair using valve-preserving techniques (artificial chordae, commissural closure, Alfieri stitch, and ring annuloplasty) was evaluated on Recurrent moderate or greater mitral regurgitation at mid-term follow-up. Minimally invasive valve-preserving mitral valve repair for Barlow's disease resulted in 0% mortality, 0% reoperation, and 11.5% moderate mitral regurgitation at a mean 29.9 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: